SEMA3B and colorectal carcinoma: Collectively, these findings indicate that SEMA3B‐AS1 suppresses CRC angiogenesis by affecting the activation of the VEGF signaling pathway, which is mediated by the SEMA3B–NRP1 axis (Figure 7H).